Innovative and adaptive strategies for new drug development are needed to maximize the potential of cell and gene therapies. CRA’s Lev Gerlovin with co-authors Walter Colasante and Pascale Diesel explain in this Cell and Gene article. Click here to read the article.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...